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Abstract
Background: Single-nucleotide polymorphisms within TP53 gene (codon 72 exon 4, rs1042522, encoding either
arginine or proline) and MDM2 promoter (SNP309; rs2279744), have been independently associated with increased
risk of several cancer types. Few studies have analysed the role of these polymorphisms in the development of
hepatocellular carcinoma.
Methods: Genotype distribution of TP53 codon 72 and MDM2 SNP309 in 61 viral hepatitis-related hepatocellular
carcinoma cases and 122 blood samples (healthy controls) from Italian subjects were determined by PCR and
restriction fragment length polymorphism (RFLP).
Results: Frequencies of TP53 codon 72 alleles were not significantly different between cases and controls. A
significant increase of MDM2 SNP309 G/G and T/G genotypes were observed among hepatocellular carcinoma
cases (Odds Ratio, OR = 3.56, 95% Confidence Limits, 95% CI = 1.3-9.7; and OR = 2.82, 95% CI = 1.3-6.4,
respectively).
Conclusions: These results highlight a significant role of MDM2 SNP309 G allele as a susceptibility gene for the
development of viral hepatitis-related hepatocellular carcinoma among Italian subjects.
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Introduction
Hepatocellular carcinoma (HCC) is the most common
liver malignancy as well as the third and the fifth cause
of cancer death in the world in men and women,
respectively [1]. HCC is an infrequent cancer in devel-
oped countries, with the exception of Southern Europe
where the incidence in men (ASR 9.8 per 100,000) is
significantly higher than in other developed regions [2].
The HCC incidence, however, has substantially
increased in Japan during the past three decades [3],
and slight increases have been reported in France and in
the United Kingdom [4,5]. The incidence rates of HCC
in the United States have historically been lower than in
many countries. However, in recent decades, HCC age-
adjusted incidence rates have doubled [6].
Etiological factors associated with the development of
the disease are well known and include infection with
the hepatitis C virus or hepatitis B virus, heavy alcohol
intake, prolonged dietary exposure to aflatoxin B1 and
primary hemochromatosis [7-9]. As for other types of
cancer, the etiology and pathogenesis of HCC is multi-
factorial and multistep [10] .T h ep r e v a l e n c eo fH C Ci n
Italy, and particularly in Southern Italy, is significantly
higher compared with other Western countries. Hepati-
tis virus infection, long-term alcohol and tobacco con-
sumption account for 87% of HCC cases in the Italian
population and, among these, 61% are attributable to
HCV infection. A recent seroprevalence survey con-
ducted in the general population of Campania Region
(Southern Italy) reported a 7.5% positivity for HCV
infection which peaked at 23.2% in the 65 years or older
age groups [11]. Thus, although the virus is highly pre-
valent only a small percentage of infected individuals
will develop liver cancer suggesting that other genetic or
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progression.
Several studies have analyzed distribution of single
nucleotide polymorphism in gene encoding for cell cycle
regulatory proteins and susceptibility to malignant dis-
eases. A common polymorphism located in exon 4 of
TP53 gene, resulting in a non-conservative arginine to a
proline change at codon 72, is known to be important
for growth suppression and apoptotic functions [12,13].
Additionally, a naturally occurring G to T sequence var-
iation (single nucleotide polymorphism - SNP309) in the
second promoter-enhancer region of the MDM2 gene
has been shown to increase the binding affinity of the
transcriptional activator Sp1 resulting in high levels of
MDM2 protein, formation of transcriptionally inactive
p53-MDM2 complexes and alteration of the p53 path-
way [14-16]. These observations are consistent with an
oncogenic function for the variant SNP309 [17].
Polymorphisms of TP53 codon 72 and MDM2
SNP309 have been previously investigated in Korean
population in which they are associated with the early
development of HCC in patients with chronic HBV
infection [18].
No studies have been conducted in HCC cases of the
Italian population. In the present study, we evaluated
the distribution of the TP53 codon 72 genotypes and
MDM2 SNP309 in a series of 61 hepatocellular carci-
noma cases comprising HCV and HBV infected patients,
and compared them with healthy controls to possibly
identify host genetic factors associated with the
increased risk of developing hepatocellular carcinoma.
Materials and methods
Patient and Tissue Samples
Liver biopsies from 53 HCV-positive, 7 HBV-positive,
one HCV/HBV-positive HCC patients and 122 negative
non-liver cancer control patients (blood samples) were
obtained with informed consent at the liver unit of the
INT “Pascale” in Naples. Each liver biopsy was divided
in two sections: the first section was stored in RNA
Later at -80°C (Ambion, Austin, TX), the second was
subjected to histopathologic examination. Only liver
biopsies determined to be hepatocellular carcinoma
were included in the study.
Genomic DNA was extracted according to published
procedures [19]. Tissue samples were digested with by
proteinase K treatment (150 μg ml-1 at 56°C for 2
hours) in 100 - 500 μl of lysis buffer (10 mM Tris-HCl,
pH 7.6, 5 mM EDTA, 150 mM NaCl, 1% SDS), followed
by DNA purification by phenol-chloroform-isoamyl
alcohol (25:24:1) extraction and ethanol precipitation in
0.3 M sodium acetate (pH 4.6). Genomic DNA from
122 blood samples from healthy controls were pre-
viously extracted and subjected to allele specific PCR of
exon 4 of TP53 and PCR-RFLP of intron 1 of MDM2
[20,21].
TP53 codon 72 and MDM2 SNP309 polymorphisms
analysis
The analysis of TP53 genotype at codon 72 was carried
out by performing an allele specific PCR in which two
independent reactions were performed for each sample:
o n es p e c i f i cf o rc o d o nC C C(encoding proline) using
the p53ProPlus (5’-GCCAGAGGCTGCTCCCCC-3’)
with p53Minus oligoprimers; the other specific for CGC
(encoding arginine), using the p53Plus with p53ArgMi-
nus (5’-CTGGTGCAGGGGCCACGC-3’) oligoprimers.
PCR amplification reactions were carried out on 100 to
200 ng genomic DNA in 50-μl reaction mixture follow-
ing amplification procedures described previously [20].
The MDM2 SNP309 was determined by PCR and
restriction fragment length polymorphism (RFLP) analy-
sis of amplified products. A 174 base pairs (bp) ampli-
mer of the MDM2 intron 1 region, containing the
MspA1 polymorphic site at nucleotide 309, was ampli-
fied with the B-MDM2-309F (5’- GGGAGTTCAGGG-
TAAAGG-3’) and the B-MDM2-309R (5’-
GACCAGCTCAAGAGGAAA-3’) oligoprimers, designed
using the Beacon Designer 2.0 software (Premier Biosoft
International, Palo Alto, CA, USA). PCR reactions were
performed in a 50-μl reaction mixture containing 100-
200 ng of target DNA, 20 pmol of each primer, 2.5 mM
MgCl2,5 0μMo fe a c hd N T Pa n d1 . 2 5Uo fH o t M a s t e r
Taq DNA polymerase (5 Prime GmbH, Hamburg, Ger-
many). DNA was amplified with the following steps: an
initial 1-min denaturation at 94°C, followed by 32 cycles
of 55°C for 45 s, 68°C for 1 min, 94°C for 30 s and a
final annealing at 55°C for 30 s with 5 min elongation at
72°C. Ten-microliter aliquots of MDM2 PCR products
were digested with MspA1 restriction enzyme, fractio-
nated by electrophoresis on a 7% polyacrylamide gel in
Tris-borate-EDTA running buffer and stained with ethi-
dium bromide for DNA band visualization by UV
transillumination.
TP53 PCR amplified products from the 61 cases were
further subjected to direct nucleotide sequencing by
Primm Srl Laboratories (Milan, Italy) using the fluores-
cent dye terminator technology and ABI 3730 DNA
sequencers (Applied BioSystems). Nucleotide sequences
were edited with Chromas Lite 2.01 (http://www.techne-
lysium.com.au/chromas.html).
Statistical analyses
The observed and expected genotype frequencies among
the study groups were analysed using the Hardy-Wein-
berg equilibrium theory. A Fisher’s exact test or c
2 test
was used, as appropriate, to compare the proportions of
TP53 and MDM2 genotypes between cases of HCC and
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was used to evaluate differences between the mean age
of cases and control group. All analyses were performed
with Epi Info 6 Statistical Analysis System Software
(6.04d, 2001, Centers for Disease Control and Preven-
tion, USA).
Differences were considered to be statistically signifi-
cant when p-values were less than 0.05.
Results
In this study were included 61 cases of hepatocellular
carcinoma (48 in males and 13 in females) and 122 can-
cer-free control subjects (all males). Table 1 summarizes
the selected characteristics of the subjects. The frequen-
cies of TP53 codon 72 genotypes has been estimated
using an allele specific PCR that specifically detects
either the TP53 proline or arginine 72- encoding
codons. A slight higher frequency of arginine allele was
observed in HCC cases compared to the controls, how-
ever, the difference did not reach statistical significance
using Yates corrected c
2 test (P = 0.696). The distribu-
tion of polymorphic alleles in cases and controls are
summarized in Table 2. The frequencies of the three
genotypes of the TP53 gene polymorphism at codon 72
among the 61 HCC cases were 4.9% (n = 3), 32.8% (n =
20) and 62.3% (n = 38) proline homozygous, heterozy-
gous and arginine homozygous, respectively, and the
corresponding figures among controls were 7.4% (n =
9), 34.4% (n = 42), and 58.2% (n = 71), respectively. The
genotype frequencies of TP5 3c o d o n7 2o fw e r ef o u n d
in Hardy-Weinberg equilibrium both in HCC cases and
healthy controls (c
2 = 0.81; df = 1; p = 0.37; and c
2=
0.63; df = 1; p = 0.43, respectively).
The MDM2 SNP309 genotypes were analyzed using a
PCR-RFLP based assay (Figure 1). The frequencies of
MDM2 SNP309 T/T, T/G and G/G genotypes among
the cases were 21.3% (n = 13), 52.5% (n = 32) and 26.2%
(n = 16), and among controls were 45.1% (n =5 5 ) ,
39.3% (n = 48) and 15.6% (n = 19), respectively. The
MDM2 SNP309 genotype frequencies were found in
Hardy-Weinberg equilibrium among cases and controls
group (c
2 = 0.16; df = 1; p = 0.69; and c
2= 2.33; df = 1;
p = 0.13, respectively). The frequencies of MDM2
SNP309 G/G and G/T genotypes were significantly
more prevalent in HCC cases (52.5%) compared with
controls (36.9%), p = 0.006. When the homozygous
MDM2 SNP309 T/T genotype was used as the reference
group, the MDM2 S N P 3 0 9G / Ga n dT / Gg e n o t y p e s
were associated with a significantly increased risk for
HCC (OR 3.56, 95% CI 1.3-9.7; OR 2.82, 95% CI 1.3-6.4,
respectively).
The combined effect of the TP53 codon72 and the
MDM2 SNP309 polymorphisms was also analysed.
However, no additional cancer risk effect associated
with TP53 codon 72 polymorphism was identified when
the risk of combined genotypes was analyzed.
Discussion
Several epidemiological studies have evaluated the asso-
ciation of TP53 codon 72 and MDM2 SNP309 poly-
morphisms and risk of or survival from several types of
cancer [22-24], but few evaluated the association of both
these polymorphisms in viral-related liver cancer and
none in hepatocellular carcinoma from Italian patients.
In the current study the TP53 codon 72 and MDM2
nucleotide 309 polymorphisms were investigated in a
series of 61 cases of hepatocellular carcinoma, mainly
associated with HCV infection, and in 122 population-
matched controls in order to verify the impact of these
gene variants on the risk of tumour development. The
TP53 codon 72 and MDM2 SNP309 genotypes were dis-
tributed in accordance with the Hardy-Weinberg equili-
brium in controls and their frequencies were in broad
agreement with those observed in previously published
studies of Caucasian subjects [25-27]. The results
showed no significant differences in the genotype distri-
bution of the TP53 codon 72 polymorphisms between
cases and controls and no increase in the frequency of
the arginine or proline alleles among HCC cases. This
observation is in agreement with previous studies
reporting no association between codon 72 genotypes
and disease severity or liver cancer in a group of 340
HCV-infected Italian subjects at different stages of dis-
ease, including 84 HCC patients, and in a group of 97
Spanish HCC patients [28,29]. Conversely, a higher fre-
quency of Pro/Pro genotype in HCC cases (13.5%) ver-
sus control subjects (6.3%) and a significant higher risk
Table 1 Characteristics and pathological features of HCC
patients and healthy controls
Variable Cases (n = 61)
n(%)
Controls (n = 122)
n(%)
Mean age, years [± SD] 68.7[± 8.87] 59.4[± 14.3]
Age, years
≤ 50 2(3.3) 12(13.1)
50-65 16(26.2) 43(45.9)
> 65 43(70.5) 38(41)
Males 48(78.7) 122(100)
Females 13(21.3)
Virus
Cases HCV-pos 53(86.9)
Cases HBV-pos 7(11.5)
Cases HCV/HBV-pos 1(1.6)
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was observed among Moroccan subjects [30]. The analy-
sis of pooled data from six case-control studies includ-
ing 836 and 279 liver cancer and 1’191 and 587 controls
of Asian and Caucasian ethnicity, respectively, showed a
significant higher risk (OR = 1.35, 95% CI 1.06 - 1.71)
for liver cancer only among Asian patients carrying the
Pro/Pro genotype [31]. A case-control study including
80 incident cases of HCC and 328 controls, nested in a
cohort of 4,841 male chronic hepatitis B, showed that
the lack of association between TP53 codon 72 Pro
allele and HCC was apparent. Indeed, in patients with
chronic liver disease there were synergistic effects
between the Pro allele and HCC family history in first-
degree relatives which conferred a risk of 7.60 (95% CI
= 2.28-25.31) for HCC development compared with sub-
jects without the Pro allele and without chronic liver
disease [32]. These observations suggest that large case-
control studies are needed in order to clarify the role of
TP53 codon 72 polymorphism in the HCC pathogenesis
in different populations.
In this study the frequencies of MDM2 SNP309 T/G
heterozygous (52.5%) and G/G homozygous (26.2%)
genotypes were significantly higher among HCC cases
compared to healthy controls (P 0.010 and P = 0.009,
respectively). The homozygous MDM2 SNP309 T/T
genotype in HCC, on the other hand, was lower (21.3%)
than that observed in controls (45.1%). The possible role
of MDM2 SNP309 polymorphism in HCC development
has been analyzed in few other geographical regions. In
Table 2 Distribution of TP53 codon 72 and MDM2 SNP309 genotypes in HCC cases and controls
HCC Cases (n = 61)
n (%)
Controls (n = 122)
n (%)
OR
a (95% CI) P Value
b
TP53 codon 72
Pro Allele 27(22.1) 60(24.6) 1
Arg Allele 95(77.9) 184(75.4) 1.15(0.7-2.0) 0.695
Pro/Pro 3(4.9) 9(7.4) 1
Pro/Arg 20(32.8) 42(34.4) 0.96(0.2-4.3) 0.875
Arg/Arg 38(62.3) 71(58.2) 1.20(0.3-5.0) 0.716
Arg/Arg + Pro/Arg 58(95.1) 113(92.6) 1.12(0.3-4.5) 0.751
MDM2 SNP309
T Allele 58(47.5) 154(63.1) 1
G Allele 64(52.5) 90(36.9) 1.89(1.2-3.0) 0.006
T/T 13(21.3) 55(45.1) 1
T/G 32(52.5) 48(39.3) 2.82(1.3-6.4) 0.010
G/G 16(26.2) 19(15.6) 3.56(1.3-9.7) 0.009
G/G + T/G 48(78.7) 67(54.9) 3.03(1.4-6.6) 0.003
aT allele or T/T MDM2 SNP309 and TP53 Pro allele or Pro/Pro codon 72 genotypes were considered as the baseline when calculating the relative crude ORs.
bYates corrected P values
Figure 1 PCR amplification followed by restriction fragment length polymorphism (PCR-RFLP) to determine MDM2 SNP309
polymorphism. MDM2 SNP309 T allele was not cleaved by MspAI endonuclease and had a single band of 174 bp. The MDM2 SNP309 G allele
was cleaved by MspAI and had two small fragments of 126 and 48 bp. The MDM2 SNP309 heterozygote had three bands of 174, 126 and 48 bp.
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ciated with higher risk of HCC in Japanese patients with
chronic hepatitis C [33], in Korean patients with chronic
HBV [18], and in Taiwanese patients infected with HBV
or HCV infection [34]. Similarly, the MDM2 309 G
allele was found to enhance the risk of viral-associated
HCC in Moroccan (Northern Africa) [35] and in Turk-
ish (Western Asia) patients [36]. Jin et al. (2011) per-
formed a metanalysis on these studies, including a total
of 738 cases and 1062 controls, to evaluate the reliability
of the associations of MDM2 SNP309 G allele with
HCC by using false-positive report probability analysis
and the Venice guidelines on genetic epidemiology [37].
The pooled OR reached 1.57 (95% CI: 1.36-1.80) for G
allele compared to T allele, using the fixed-effect model,
indicating that this SNP may be used as a predictive
molecular marker for the screening of populations with
high risk of HCC [37].
Overexpression of the MDM2 protein has an onco-
genic effect through the reduction of p53 levels with the
consequent attenuation of the p53 DNA damage
response that allows increased cell proliferation and
inhibition of apoptosis, providing advantageous signals
for tumor cell survival [38-40]. The study by Bond et al.
(2004) showed that MDM2 protein levels in homozy-
gous and heterozygous SNP309 G cell lines are on aver-
age 4-fold and 1.9 fold higher, respectively, than TT cell
lines [14]. Furthermore, Hirata et al. reported that renal
cell carcinoma tissue with G/G and G/T genotypes were
more frequently positively stained for MDM2 than that
with the TT genotype (50% and 26%, respectively, versus
13%) [41]. The proper regulation of MDM2 levels has
been shown to be critical for p53 tumour suppression,
and even a modest change in levels could affect the p53
pathway and, subsequently, increase the risk of cancer
development in mouse models [42]. MDM2 binds
directly to and inhibits p53 by regulating its location,
stability and ability to activate transcription [14]. Several
reports have shown that HCV proteins (NS3, NS5A and
NS5B) can modulate activity and/or expression of p53
and may interfere with normal regulation of cell growth
[43-45]. This implies that MDM2 polymorphism
together with viral hepatitis protein may result in a
cumulative effect on the inactivation of p53 function.
This study has limitations, including the modest sam-
ple size and the fact that cases were not well matched
for age and sex with the control subjects. Although Ita-
lian blood donors may be good representatives of the
general population, they are younger than HCC patients
due to age limit and health requirements for blood
donation. However, being fulfilled the Hardy Weinberg
equilibrium for the allelic frequencies of both TP53 and
MDM2 polymorphisms in the control group, it may be
excluded that age and sex limitations have introduced
significant bias in the study.
In conclusion, these results provide the first evidence
that the MDM2 SNP309 polymorphism represents a
risk factor for viral hepatitis-related HCC in the Italian
population. Conversely, the TP53 polymorphism at
codon 72 seems not to be a potential risk factor for
development of HCC in Italian patients.
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